Paloxi-IV 0.25 Injection

Uses of Paloxi-IV 0.25 Injection

• Chemotherapy-induced nausea and vomiting
• Post-operative nausea and vomiting

How Paloxi-IV 0.25 Injection works?

Paloxi-IV 0.25 Injection blocks the action of serotonin, which induces nausea and vomiting (serotonin is a chemical that carries messages between nerve cells in the brain and throughout the body).

Side Effcets of Paloxi-IV 0.25 Injection

• Diarrhea
• Difficulty with bowel movements
• Dry mouth
• Chills
• Blurred vision
• Difficulty in breathing
• Chest discomfort
• Dizziness
• Injection site pain
• Constipation
• Headache
• Difficulty in passing urine
• Dizziness, jerky body movements, abnormal heart rate, cough and shortness of breath, nosebleed, hives, fever, pain at the injection site (in children)

Quick Suggestions:

• You have been prescribed Paloxi-IV 0.25 Injection for the prevention of nausea and vomiting caused after surgery or due to chemotherapy and radiotherapy.
• Unlike some other nausea medicines, the side effects of Paloxi-IV 0.25 Injection are relatively mild.
• It is fast-acting and starts working within 30 minutes.
• If you vomit within one hour of taking a dose, take another dose.
• Avoid heavy meals and try eating small nourishing snacks throughout the day. Also, sip water regularly to help avoid dehydration.

Indication of Paloxi-IV 0.25 Injection

Palonosetron is used to treat-

• To control nausea and vomiting that occurs as a result of chemotherapy (treatment of cancer)
• For postoperative nausea and vomiting following surgery

Pharmacology

Palonosetron is a medication that blocks the 5-HT3 receptor, which is responsible for causing nausea and vomiting when stimulated by serotonin released from cells in the small intestine due to chemotherapy. This drug has a strong affinity for the 5-HT3 receptor and does not affect other receptors.

Dosage & Administration of Paloxi-IV 0.25 Injection

Typical dosage:

• Adults should take 0.5 mg of the tablet once a day. Adult IV dosage: A single 0.075 mg IV dose should be given over 10 seconds.

Nausea and vomiting caused by chemotherapy: 

• Adult tablet dosage: 0.5 mg, given 1 hour before the start of chemotherapy. Adult IV dosage: A single 0.25 mg IV dose should be given every 30 seconds for about 30 minutes.
• Paloxi-IV 0.25 Injection may be given to children above 1 month in doses as advised by a doctor based on the child's body weight.

Paloxi-IV 0.25 Injection will be injected intravenously into your body only by your doctor or nurse. Your doctor will administer the correct dose and duration for you depending on your age, body weight, and disease condition.

Interaction

In controlled clinical trials, palonosetron injection was administered safely with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents. Palonosetron had no effect on the antitumor activity of cisplatin, cyclophosphamide, cytarabine, doxorubicin, or mitomycin C in murine tumor models.

Contraindications

Palonosetron is not recommended for patients who have a history of hypersensitivity to the drug or any of its ingredients.

Pregnancy & Lactation

• Paloxi-IV 0.25 Injection is generally considered safe to use during pregnancy. Animal studies have shown low or no adverse effects on the developing baby; however, there are limited human studies.
• Paloxi-IV 0.25 Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.

Precautions & Warnings

• When hypercalcemia occurs, the drug must be stopped immediately.
• Increased fluid intake should also be recommended for patients who have a history of kidney stone formation.
• It works quickly and begins working within 30 minutes.
• Take another dose if you vomit within one hour of taking one.
• Avoid large meals and instead, opt for small nourishing snacks throughout the day.
• Drink water on a regular basis to avoid dehydration.

Storage Conditions

Store at or below 30°C, away from light and moisture. Keep out of reach of children.